http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1009143-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_082c49592d104a4189c1c9b88de2f052 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 |
| filingDate | 2016-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_031e9c66be59f7b4c0eae78635571175 |
| publicationDate | 2017-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GR-1009143-B |
| titleOfInvention | Prototype Therapeutic Action of Selected Aminotrhydrofurans against Neurodegenerative and Neurodevelopmental Diseases |
| abstract | This invention relates to tetrahydro-N, N-dimethyl-2,2-biphenyl-3-furan-methanamine (AE37), tetrahydro-N-methyl-2,2-biphenyl-3-furanomethanamine (AE37Met), the enantiomers and their pharmaceutically acceptable salts, which exhibit a novel combination of selective antagonistic properties on extracellular glutamatergic NMDA receptors in the brain, with a unique selectivity to sigma-1 receptors (with sigma-2 having zero chemosensitivity). with competitions of sodium channels and M2 muscarinic substrates and, above all, moderately negative allosteric regulation of gamma-aminobutyric acid (GABA-A) A receptors in the brain, thereby developing a unique action against impaired glutamatergic and GABAergic brain functions, which characterize neovascular and nephrotoxic neurons and their fatal evolution. |
| priorityDate | 2016-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.